【摘要】 目的观察曲伏前列素滴眼液治疗原发性开角型青光眼的疗效及安全性。方法原发性开角型青光眼患者46例(68眼),观察用药前和给予0.04g·L-1曲伏前列腺素滴眼液后4周、12周、24周眼压;每晚8点一眼1次,每次1滴。测量一日内时间点为830、1130、1430、1730的眼压,每个时间点测量3次取其平均值。观察用药前、用药24周后视力、视野、C/D比值及副作用。结果用药前眼压为22～29(25.60±3.85)mmHg(1kPa=7.5mmHg),用药4周后眼压13～22(15.10±2.39)mmHg(t=495.93,P<0.01),用药12周后眼压14～23(15.40±3.57)mmHg(t=456.16,P<0.01),用药24周后眼压13～23(15.50±3.65)mmHg(t=410.20,P<0.01),治疗24周后同一天4个不同时间点眼压变化值比较差异无统计学意义(P>0.05)。用药前后矫正视力、C/D比值及视野无明显改变。6眼结膜充血较重,并随用药时间延长减轻至缓解。未发现严重副作用,所有患者均未因副作用停药。结论曲伏前列素滴眼液能安全有效地降低原发性开角型青光眼眼压,使用方便,依从性好,副作用小,有望成为理想的治疗原发性开角型青光眼的一线药物。更多还原

【Abstract】 Objective To investigate the effect and safety of travoprost(travatan) in treatment of primary open angle glaucoma.Methods A total of 68 eyes of 48 patients with primary open angle glaucoma were chosen.All eyes were applied with travoprost,one drop at 8:00 pm once daily.The intraocular pressure(IOP) was measured at 8:30,11:30,14:30,17:30 daily,three measurements at the same time point.The visual acuity,visual field,C/D value and complications before treatment and 24 weeks after treatment were observed.Results IOP before treatment was(25.60±3.85) mmHg(1 kPa=7.5 mmHg,from 22 mmHg to 29 mmHg),which at 4 weeks after treatment was decreased to(15.10±2.39)mmHg(from 13 mmHg to 22 mmHg)(t=495.93,P<0.01),at 12 weeks was(15.40±3.57) mmHg(from 14 mmHg to 23 mmHg)(t=456.16,P<0.01),at 24 weeks was(15.50±3.65) mmHg(from 13 mmHg to 23 mmHg)(t=410.20,P<0.01).There was not statistical in IOP changes between four time points in the same day at 24 weeks after treatment(P>0.05).There were no change of visual acuity,C/D value and visual field before and after treatment.Six eyes appeared serous conjunctival congestion,and the symptom became mild with further long term treatment.There was no serous complication,and no cases interrupted the treatment because of complication.Conclusion Travoprost is safe and effective in down-regulating IOP in patients with primary open angle glaucoma,it is convenient with better compliance and less complication,which will be as first line treating drug for primary open angle glaucoma.更多还原